Related Experiment Video
Updated: Jul 3, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history
Thomas Rudolph1, Martin Wilhelm Kurz, Elisabeth Farbu
1Department of Neurology, Stavanger University Hospital, Postboks 8100, 4068 Stavanger, Norway. mokum99@online.no
Abstract:
Familial amyloid polyneuropathy (FAP) is rare and most commonly caused by the Val30Met mutation of the transthyretin (TTR) gene. Beside polyneuropathy, other complications due to amyloid deposits occur, but may vary in phenotype. The mutation tends to occur in endemic clusters. We describe a 65-year-old man from a non-endemic FAPVal30Met area who developed a progressive generalized painless axonal sensorimotor polyneuropathy with mild autonomic involvement and absent FAP symptoms in the family. Nerve biopsy showed amyloid deposits, staining with TTR-antibodies on immunohistochemistry. After DNA-sequencing of the TTR gene, the diagnosis of FAP Val30Met was made. Late-onset FAP Val30Met is a progressive and fatal disorder with varying penetrance, and may occur in non-endemic areas and cases without a family history.
Insights
Familial amyloid polyneuropathy (FAP) due to the TTR Val30Met mutation can occur in non-endemic areas. This rare genetic disorder may present without a family history and with varied symptoms.
Area of Science:
- Neurology
- Genetics
- Pathology
Background:
- Familial amyloid polyneuropathy (FAP) is a rare, progressive, and fatal genetic disorder.
- It is most commonly caused by the Val30Met mutation in the transthyretin (TTR) gene.
- FAP often presents with polyneuropathy and tends to occur in endemic clusters.
Observation:
- A 65-year-old man from a non-endemic region presented with progressive, painless axonal sensorimotor polyneuropathy.
- The patient exhibited mild autonomic dysfunction.
- There was no prior family history of FAP symptoms.
Findings:
- Nerve biopsy confirmed amyloid deposits with TTR-antibody staining via immunohistochemistry.
- DNA sequencing identified the TTR Val30Met mutation.
- The diagnosis of late-onset FAP Val30Met was established.
Implications:
- Late-onset FAP Val30Met can manifest in non-endemic areas.
- The disorder may occur in individuals without a family history, indicating variable penetrance.
- This case highlights the importance of considering FAP Val30Met even in atypical presentations.
More Related Videos
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Related Concept Videos
Alzheimer Disease l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Diabetic Neuropathy
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...